Angiogenesis
Angiogenesis inhibitors are compounds that interfere with the formation of new blood vessels, a process critical in cancer growth and metastasis. By inhibiting angiogenesis, these compounds can restrict the blood supply to tumors, slowing or halting their growth. Angiogenesis inhibitors are essential in cancer research and therapeutic development, providing insights into the mechanisms of tumor progression and offering potential treatments for cancer and other angiogenesis-related diseases. At CymitQuimica, we offer a wide range of high-quality angiogenesis inhibitors to support your research in oncology and vascular biology.
Subcategories of "Angiogenesis"
- BTK(166 products)
- Bcr-Abl(117 products)
- EGFR(578 products)
- FAK(72 products)
- FLT(86 products)
- Fibroblast Growth Factor Receptor (FGFR)(179 products)
- JAK(244 products)
- PDGFR(129 products)
- RAAS(89 products)
- Src(82 products)
- Syk(37 products)
- Thrombin(56 products)
- VDA(2 products)
- VEGFR(242 products)
Show 6 more subcategories
Found 2369 products of "Angiogenesis"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
Atrasentan
CAS:Controlled ProductApplications Atrasentan is a selective antagonist of the endothelin-A (ETA) receptor and binds selectively to the ETA receptor, which may result in inhibition of endothelin-induced angiogenesis and tumor cell proliferation.
References Bax, W., et al.: Trends Pharmacol. Sci., 15, 379 (1994); Winn, M., et al.: J. Med. Chem., 39, 1039 (1996); Wu-Wong, J., et al.: J. Pharmacol. Exp. Ther., 281, 791 (1997);Formula:C29H38N2O6Color and Shape:Off-WhiteMolecular weight:510.62GW843682X
CAS:GW843682X (GW843682) is a selective and ATP-competitive inhibitor of PLK1 and PLK3 (IC50s = 2.2 nM and 9.1 nM).Formula:C22H18F3N3O4SPurity:99.92%Color and Shape:SolidMolecular weight:477.46E3330
CAS:E3330 is a potent and selective APE1(Ref-1) inhibitor, which suppressed NF-kappa B DNA-binding activity.Formula:C21H30O6Purity:99.52%Color and Shape:SolidMolecular weight:378.46SU11274
CAS:SU11274 (Met Kinase Inhibitor)(IC50=10 nM) is a specific Met inhibitor. It shows no significant effects on PGDFRβ, EGFR or Tie2.Formula:C28H30ClN5O4SPurity:98.62% - 99.53%Color and Shape:Orange PowderMolecular weight:568.09Ref: TM-T6154
1mg44.00€2mg56.00€5mg92.00€10mg142.00€25mg268.00€50mg442.00€100mg652.00€1mL*10mM (DMSO)142.00€Bucillamine
CAS:Bucillamine (DE019) protects against Ischemia/reperfusion injury in high-risk organ transplants and inhibits the production of VEGF.Formula:C7H13NO3S2Purity:99.47%Color and Shape:SolidMolecular weight:223.31CP-547632
CAS:CP-547632 is an oral ATP-competitive inhibitor of VEGFR-2/FGF kinase with IC50s of 11/9 nM, highly selective, has antitumor activity.Formula:C20H24BrF2N5O3SPurity:99.14%Color and Shape:SolidMolecular weight:532.4Icotinib Hydrochloride
CAS:Icotinib Hydrochloride, an oral EGFR inhibitor (BPI-2009H), may halt cancer growth by blocking EGFR signaling.Formula:C22H22ClN3O4Purity:99.89%Color and Shape:SolidMolecular weight:427.88TAK-285
CAS:TAK-285 is a novel dual HER2 and EGFR(HER1) inhibitor, >10-fold selectivity for HER1/2 than HER4, less potent to MEK1/5, c-Met, Aurora B, Lck, CSK etc.Formula:C26H25ClF3N5O3Purity:99.73%Color and Shape:SolidMolecular weight:547.96Ref: TM-T6039
1mg38.00€5mg80.00€10mg120.00€25mg216.00€50mg354.00€100mg512.00€200mg727.00€1mL*10mM (DMSO)96.00€EGFR-IN-54
CAS:EGFR-IN-54 (Compound 3c) is a potent inhibitor of EGFR (IC50: 1.623 μM) and is toxic to cancer cells.Formula:C17H14N4O4S3Color and Shape:SolidMolecular weight:434.51NSC114792
CAS:NSC114792 is a selective JAK3 inhibitor.Formula:C26H32N4O2SPurity:98%Color and Shape:SolidMolecular weight:464.62FLT3-IN-11
CAS:FLT3-IN-11, an oral FLT3 kinase inhibitor: potent, selective, IC50 - wild-type 7.22 nM, FLT3-D835Y 4.95 nM, anti-AML IC50 3.2 nM for MV4-11.Formula:C20H25F3N6OColor and Shape:SolidMolecular weight:422.45EGFR-IN-89
CAS:EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM againstFormula:C26H31FN8O2SPurity:98%Color and Shape:SolidMolecular weight:538.64PF-00337210
CAS:PF-00337210, an oral VEGFR2 inhibitor, may hinder endothelial and tumor cell growth, reducing angiogenesis and potentially causing cancer cell death.Formula:C26H27N3O5Color and Shape:SolidMolecular weight:461.51VEGFR-2-IN-20
CAS:VEGFR-2-IN-20 (Compound 7) is a highly effective VEGFR inhibitor with significant potential for cancer research [1].Formula:C20H20N4O3SColor and Shape:SolidMolecular weight:396.46J-1048
CAS:J-1048, an activin receptor-like kinase 5 (ALK5) inhibitor, effectively suppresses TAA-induced liver fibrosis in mice through specific inhibition of the TGF-β/Formula:C23H17FN6S2Color and Shape:SolidMolecular weight:460.55SUN13837
CAS:SUN13837, an oral FGFR modulator, crosses the BBB and shows neuroprotective promise.Formula:C21H29N5O2Color and Shape:SolidMolecular weight:383.49TYK2-IN-11
CAS:TYK2-IN-11 (5B) selectively inhibits TYK2 (IC50: 0.016 nM) and JAK1 (IC50: 0.31 nM), aiding autoimmune and inflammatory disease research.Formula:C18H17N5O3SColor and Shape:SolidMolecular weight:383.42EGFR/HER2-IN-3
CAS:EGFR/HER2-IN-3 (Compound ZINC21942954) is a dual EGFR and HER2 inhibitor.Formula:C26H23N5O3Color and Shape:SolidMolecular weight:453.49CGP60474
CAS:CGP60474 is an inhibitor of VEGFR-2 (IC50 = 84 nM) and an inhibitor of ATP-competitive PKC.Formula:C18H18ClN5OPurity:98.81%Color and Shape:SolidMolecular weight:355.82Ref: TM-T14943
1mg34.00€2mg46.00€5mg71.00€10mg92.00€25mg177.00€50mg314.00€100mg518.00€1mL*10mM (DMSO)78.00€Momelotinib Mesylate
CAS:Momelotinib Mesylate is an ATP-competitive JAK1/JAK2 inhibitor (IC50: 11 nM/18 nM). It has 10-fold selectivity versus JAK3.Formula:C24H26N6O5SPurity:98%Color and Shape:SolidMolecular weight:510.57FLT3-IN-18
CAS:FLT3-IN-18: potent, selective FLT3 inhibitor, IC50 0.003 μM, induces apoptosis, G1 arrest, blocks FLT3/STAT5, potential in AML research.Formula:C26H36N8OColor and Shape:SolidMolecular weight:476.62(R)-Elsubrutinib
CAS:(R)-Elsubrutinib ((R)-ABBV-105) is a Btk inhibitor and an isomer of Elsubrutinib, suitable for inflammation research.Formula:C17H19N3O2Purity:99.05%Color and Shape:SolidMolecular weight:297.35Ref: TM-T72653
1mg145.00€5mg250.00€10mg340.00€25mg573.00€50mg879.00€100mg1,314.00€1mL*10mM (DMSO)462.00€FGFR2-IN-1
CAS:FGFR2-IN-1 is an FGFR inhibitor that inhibits FGFR1, FGFR2, and FGFR3, and can be used to study FGFR2-associated cancers.Formula:C22H19N3O2Purity:98.71%Color and Shape:SolidMolecular weight:357.41YH-306
CAS:YH-306 (TRV055 acetate ) is a modulator of the FAK signaling pathway that acts by suppressing colorectal tumor growth and metastasis.Formula:C19H18N2O2Purity:98.06%Color and Shape:SolidMolecular weight:306.36EGFR-IN-69
CAS:EGFR-IN-69: Potent EGFR inhibitor for NSCLC research; IC50: 4.3-25.6 nM against various EGFR mutations.Formula:C31H37Cl2N7O3SColor and Shape:SolidMolecular weight:658.64TGFBR1-IN-1
CAS:TGFBR1-IN-1 is an inhibitor of ALK5 (IC50 of 10-100 nM).Formula:C23H17N5O2SPurity:98%Color and Shape:SolidMolecular weight:427.48VEGFR2 Kinase Inhibitor II
CAS:VEGFR2 kinase inhibitor II: Reversible, cell-permeable, targets VEGFR2 (IC50=70nM), less effective on PDGFRβ (IC50=920nM). Blocks VEGF/PDGF-stimulated growth.Formula:C17H15BrN2OColor and Shape:SolidMolecular weight:343.22BLK-IN-1
CAS:BLK-IN-1 selectively blocks BLK and BTK with IC50s of 18.8 and 20.5 nM, used in cancer research.Formula:C29H23F3N6O3Color and Shape:SolidMolecular weight:560.53GZD856
CAS:GZD856 is an orally bioavailable PDGFRα/β inhibitor (IC50s: 68.6 and 136.6 nM) with anti-lung cancer activities.Formula:C29H27F3N6OPurity:98%Color and Shape:SolidMolecular weight:532.56EGFR-IN-31
CAS:EGFR-IN-31: Potent EGFR inhibitor, targets mutations & overexpression in NSCLC; potential cancer research compound. (WO2021185298A1, 2)Formula:C32H36FN7O2Color and Shape:SolidMolecular weight:569.67FLT3/D835Y-IN-1
CAS:FLT3/D835Y-IN-1, an oral FLT3 inhibitor (IC50: FLT3 - 0.26 nM, D835Y - 0.18 nM), shows anticancer potential in AML research.Formula:C22H21N5O3Color and Shape:SolidMolecular weight:403.43ALK2-IN-5
CAS:ALK2-IN-5, a pyrazolopyrimidine compound, serves as an inhibitor of ALK2 and FGFR, targeting disorders linked with their activity, including cancer [1].Formula:C24H32N8O2Color and Shape:SolidMolecular weight:464.56FGFR-IN-13
CAS:FGFR-IN-13 (compound III-30), an irreversible covalent inhibitor of the fibroblast growth factor receptor (FGFR), effectively modulates signaling through FGFR1 (IC 50 = 0.20 ± 0.02 nM) and FGFR4 (IC 50 = 0.40 ± 0.03 nM). It suppresses the expression of crucial proteins such as total-PARP and Bcl-2, while enhancing the expression of Cleaved-PARP and Bax in a dose-dependent manner. Notably, FGFR-IN-13 demonstrates considerable antitumor and oral activity [1].Formula:C23H21N5O3Molecular weight:415.44OICR-0547
CAS:OICR-0547 is an inactive derivative of OICR-9429 and is commonly used as a negative control for OICR-9429.Formula:C28H29F3N4O4Purity:98%Color and Shape:SolidMolecular weight:542.55SB-633825
CAS:SB-633825 can inhibit cancer cell growth and angiogenesis.Formula:C28H25N3O3SPurity:98%Color and Shape:SolidMolecular weight:483.58BCR-ABL1-IN-1
CAS:BCR-ABL1-IN-1: potent, orally active ABL kinase inhibitor with high specificity, promising for CNS research.Formula:C18H12F3N3O2Color and Shape:SolidMolecular weight:359.3EGFR-IN-60
CAS:EGFR-IN-60: oral anticancer drug, inhibits EGFR/JAK3, effective on H1975/A431 cells, promotes apoptosis.Formula:C28H28Cl2N6OColor and Shape:SolidMolecular weight:535.47IHMT-TRK-284
CAS:IHMT-TRK-284: Oral type II TRK inhibitor; targets TRKA, TRKB, TRKC (IC50s: 10.5, 0.7, 2.6 nM); selective and anti-tumor effective.Formula:C25H27N7OSColor and Shape:SolidMolecular weight:473.59Spebrutinib besylate
CAS:Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).Formula:C28H28FN5O6SPurity:98%Color and Shape:SolidMolecular weight:581.62JAK-IN-14
CAS:JAK-IN-14 (compound 16) is a specific JAK1 inhibitor. It prevents JAK1 phosphorylation by binding to the active site of JAK in immune, inflammation and cancer.Formula:C19H15FN4OPurity:98.27%Color and Shape:SolidMolecular weight:334.35Ref: TM-T9764
1mg81.00€5mg170.00€10mg268.00€25mg555.00€50mg888.00€100mg1,414.00€200mg1,882.00€1mL*10mM (DMSO)178.00€ZT55
CAS:ZT55: Oral JAK2 inhibitor, IC50: 0.031 μM, hinders JAK2 V617F HEL cell growth, induces apoptosis, arrests cell cycle, effective in mice HEL tumor studies.Formula:C17H16N2O3Color and Shape:SolidMolecular weight:296.32VEGFR-2-IN-24
CAS:VEGFR-2-IN-24 is a potent inhibitor of VEGFR-2 (IC50: 0.22 μM) and can be used to study tumors.Formula:C28H23N3O6SColor and Shape:SolidMolecular weight:529.56FGFR4-IN-11
CAS:FGFR4-IN-11: selective, covalent FGFR4 inhibitor; IC50=2.1 nM; blocks FGF19 pathway; anticancer.Formula:C29H29N5O5Color and Shape:SolidMolecular weight:527.57c-Met-IN-14
CAS:c-Met-IN-14: selective c-Met kinase inhibitor, IC50 2.89 nM, anticancer, stops G2/M phase, induces A549 cell apoptosis.Formula:C34H38ClFN4O7SColor and Shape:SolidMolecular weight:701.2BIBX 1382 Dihydrochloride
CAS:BIBX 1382 Dihydrochloride blocks Lassa/Ebola entry, aids in studying virus-host interactions, and hints at kinase targets for therapy.Formula:C18H21Cl3FN7Color and Shape:SolidMolecular weight:460.76EGFR-IN-26
CAS:EGFR-IN-26 is an EGFR inhibitor that can be used in cancer research.Formula:C29H34N6O3Color and Shape:SolidMolecular weight:514.62TRK/ALK-IN-1
TRK/ALK-IN-1: Potent dual TRK & ALK inhibitor; IC50s: 2.2nM (TRKA), 9.3nM (ALK WT), 38nM (ALK L1196M); cancer research potential.Formula:C31H35ClF2N8O2SColor and Shape:SolidMolecular weight:657.18FGFR3-IN-1
CAS:FGFR3-IN-1 (compound 1) is a fibroblast growth factor receptor (FGFR) inhibitor that inhibits FGFR1 (IC50: 40 nM), FGFR2 (IC50: 5.1 nM) and FGFR3 (IC50: 12 nM).Formula:C28H39N9O3SColor and Shape:SolidMolecular weight:581.73CAY10717
CAS:CAY10717 inhibits 34/104 kinases at 100 nM, targets EGFR/ABL/B-Raf mutations, kills various cancer cells, and blocks HUVEC growth.Formula:C29H25F3N6O3Color and Shape:SolidMolecular weight:562.54PF-06651481-00
CAS:PF-06651481-00 (Bosutinib Isomer I) is a Bosutinib analog and a Bcr-Abl inhibitor.
Formula:C26H29Cl2N5O3Purity:97.01%Color and Shape:SolidMolecular weight:530.45EGFR-IN-73
CAS:EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].Formula:C19H17ClFN3O4Purity:98%Color and Shape:SolidMolecular weight:405.81EGFR-IN-49
CAS:EGFR-IN-49 selectively inhibits EGFR mutations T790M (IC50: 65 nM) & T790M/L858R (IC50: 13.6 nM), triggering apoptosis dose-dependently.Formula:C22H15N5O2SColor and Shape:SolidMolecular weight:413.45TIE-2/VEGFR-2 kinase-IN-1
CAS:TIE-2/VEGFR-2 kinase-IN-1 synthesizes inhibitors for angiogenesis-related disease research.Formula:C13H11N3O2Color and Shape:SolidMolecular weight:241.25Epertinib
CAS:Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).Formula:C30H27ClFN5O3Purity:98%Color and Shape:SolidMolecular weight:560.02Erbstatin
CAS:Erbstatin is a tyrosine-protein kinase inhibitor. When combined with foroxymithine, it has antineoplastic activity against L-1210 leukemia.Formula:C9H9NO3Color and Shape:SolidMolecular weight:179.17PD-173956
CAS:PD-173956 is an inhibitor of the Src family tyrosine kinases.Formula:C20H13Cl2FN4OColor and Shape:SolidMolecular weight:415.25Syk-IN-1
CAS:Syk-IN-11 is a selective Syk inhibitor.Formula:C18H22N8OColor and Shape:SolidMolecular weight:366.42LBW242
CAS:LBW242: oral 3-mer Smac mimetic, IAP inhibitor, targets multiple myeloma, enhances TRAIL/chemo death in ovarian cancer, active on mutant FLT3 cells.Formula:C27H42N4O2Purity:98%Color and Shape:SolidMolecular weight:454.65EGFR-IN-55
CAS:"EGFR-IN-55 targets EGFRWT (70 nM IC50) & EGFRL858R/T790M (3.9 nM IC50), halts NCI-H1975 cell cycle in G0/G1, showing anticancer properties."Formula:C25H25Cl2N7O2Color and Shape:SolidMolecular weight:526.42PDZ1i
CAS:PDZ1i: potent MDA-9/Syntenin inhibitor; crosses blood-brain barrier; targets GBM, FAK, EGFRvIII; lowers MMP secretion.Formula:C28H26N8O4Color and Shape:SolidMolecular weight:538.56EAI001
CAS:EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.Formula:C19H15N3O2SPurity:99.94%Color and Shape:SolidMolecular weight:349.41CP-690550A
CAS:Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases.Formula:C15H21N5O2Color and Shape:SolidMolecular weight:303.36SSR128129E free acid
CAS:SSR128129E free acid is an orally available and allosteric inhibitor of FGFR(IC50 of 1.9 μM for FGFR1).Formula:C18H16N2O4Purity:98%Color and Shape:SolidMolecular weight:324.33Esuberaprost Sodium
CAS:Famitinib (SHR1020), an oral drug, inhibits c-kit, VEGFR-2, and PDGFRβ (IC50: 2.3/4.7/6.6 nM) and triggers apoptosis in gastric cancer.Formula:C23H27FN4O2Color and Shape:SolidMolecular weight:410.48CGP52411
CAS:CGP52411 is an orally active, and ATP-competitive inhibitor of EGFR (IC50: 0.3 μM).Formula:C20H15N3O2Purity:99.78%Color and Shape:SolidMolecular weight:329.35CHMFL-BTK-01
CAS:CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.Formula:C38H41N5O5Purity:98%Color and Shape:SolidMolecular weight:647.76Con B-1
CAS:ConB-1 is a potent and selective ALK inhibitor with low toxicity to normal cells .Formula:C38H52ClN7O6SColor and Shape:SolidMolecular weight:770.38TG 100572
CAS:TG 100572 is a inhibitor of multi-targeted kinase which inhibits receptor tyrosine kinases and Src kinases(IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2Formula:C26H26ClN5O2Purity:98%Color and Shape:SolidMolecular weight:475.97PD 166326
CAS:PD166326, a pyridopyrimidine inhibitor, targets Src & Abl tyrosine kinases (IC50: 6 nM & 8 nM) and exhibits antileukemic effects.Formula:C21H16Cl2N4O2Color and Shape:SolidMolecular weight:427.28MAX-40279 hydrochloride
CAS:MAX-40279 HCl: potent FLT3/FGFR inhibitor; potential in AML research.Formula:C22H24ClFN6OSColor and Shape:SolidMolecular weight:474.98Nazartinib mesylate
CAS:Nazartinib mesylate is a novel, covalent mutant-selective inhibitor of EGFR (Ki and Kinact: 31 nM and 0.222/min on EGFR(L858R/790M) mutant).Formula:C27H35ClN6O5SPurity:98%Color and Shape:SolidMolecular weight:591.12MDK5466
CAS:MDK5466 is an Flt3 inhibitor that acts by preventing glutamate-induced cell death.Formula:C21H23N3OSPurity:98%Color and Shape:SolidMolecular weight:365.49HIV-IN-6
CAS:HIV-IN-6, an anti-HIV agent, blocks replication by targeting SFKs like Hck involved with Nef protein.Formula:C20H16N4O3SPurity:97.78%Color and Shape:SolidMolecular weight:392.43Lavendustin C6
CAS:Lavendustin C6 is a effective tyrosine kinase inhibitor.Formula:C20H25NO5Color and Shape:SolidMolecular weight:359.42TRK II-IN-1
CAS:TRK II-IN-1: potent type II TRK inhibitor; IC50s: TRKA (3.3 nM), TRKB (6.4 nM), TRKC (4.3 nM), TRKA G667C (9.4 nM); also targets FLT3, RET, VEGFR2.Formula:C29H31F3N8OPurity:98%Color and Shape:SolidMolecular weight:564.6THS-044
CAS:THS-044 (N-[2-Nitro-4-(Trifluoromethyl)phenyl]morpholin-4-Amine) binding stabilizes the HIF2α PAS-B folded state with a kd of 2 μM and regulates HIF2 activityFormula:C11H12F3N3O3Purity:99.89%Color and Shape:SolidMolecular weight:291.23ER-27319
CAS:ER-27319, an acridone derivative, serves as a potent and selective inhibitor of spleen tyrosine kinase (SYK), effectively impeding both the tyrosineFormula:C20H22N2O5Purity:98%Color and Shape:SolidMolecular weight:370.4VEGFR-2/BRAF-IN-2
VEGFR-2/BRAF-IN-2 inhibits VEGFR-2, BRAF V600E, BRAF WT (IC50: 0.111/0.089/0.071 µM); induces G1 arrest and apoptosis.Formula:C26H21ClF3N5O3S2Color and Shape:SolidMolecular weight:608.05A-420983
CAS:A-420983 is a novel potent Lck inhibitor, exhibiting oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection.Formula:C33H39N9O2Color and Shape:SolidMolecular weight:593.72EGFR-IN-88
CAS:EGFR-IN-88 (Compound 4i), an EGFR inhibitor with an IC50 of 87 nM, exhibits cytotoxic effects on A549 cells at an IC50 of 3.902 μM and can induce cell apoptosisFormula:C22H18Cl2N4O2SPurity:98%Color and Shape:SolidMolecular weight:473.37BAY 2476568
CAS:BAY 2476568 is a selective and potent EGFR inhibitor that acts on both wild-type EGFR (IC50 <0.2 nM) and mutant EGFR (IC50 <0.2 nM).Formula:C24H27FN4O4Color and Shape:SolidMolecular weight:454.49ZK-304709 HCl
CAS:ZK-304709 is an oral multitarget tumor growth inhibitor with activity against cell-cycle progression and angiogenesis.Formula:C22H29ClN6O2Color and Shape:SolidMolecular weight:444.96FGFR4-IN-5
CAS:FGFR4-IN-5: potent, selective FGFR4 inhibitor, IC50 6.5 nM, strong in vivo anti-tumor effect, for liver cancer research.Formula:C23H23Cl2N5O5Color and Shape:SolidMolecular weight:520.37DPPY
CAS:DPPY inhibits EGFR, BTK, JAK3 (IC50<10 nM), curbs B-cell lymphoma growth, and may be studied for IPF treatment.Formula:C25H26ClN7O3Color and Shape:SolidMolecular weight:507.97T-1840383
CAS:T-1840383 blocks VEGFR-2 and c-Met phosphorylation in endothelial and cancer cells.Formula:C30H25ClFN5O4Color and Shape:SolidMolecular weight:574PDGFRα/FLT3-ITD-IN-1
CAS:PDGFRα/FLT3-ITD-IN-1 are potent inhibitors of PDGFRα/FLT3, and their IC50 values are greater than 0.036 and 0.003 μM, respectively.Formula:C27H39N9OColor and Shape:SolidMolecular weight:505.66UniPR1331
CAS:UniPR1331 is a novel selective antagonist of the Eph-ephrin system.Formula:C35H48N2O4Color and Shape:SolidMolecular weight:560.77BSc5371
CAS:BSc5371: Irreversible FLT3 inhibitor; Kds 0.83-5.8 nM for various FLT3 mutants including wild type.Formula:C24H31N5O4SPurity:98%Color and Shape:SolidMolecular weight:485.6BPIQ-II (hydrochloride)
CAS:BPIQ-II, a selective EGFR inhibitor with an IC50 of 8 pM, targets ATP sites and halts EGF signals inside cells.Formula:C15H11BrClN5Color and Shape:SolidMolecular weight:376.64KRC-108
CAS:KRC-108 is a potent kinase inhibitor targeting Ron, Flt3, TrkA, and c-Met with strong anti-proliferative effects on various cancer cells.Formula:C20H20N6OColor and Shape:SolidMolecular weight:360.41JAK3/BTK-IN-5
CAS:JAK3/BTK-IN-5 is a potent dual inhibitor targeting JAK3 and BTK with synergistic effects, valuable for related autoimmune disease research.Formula:C19H22ClN7O2Color and Shape:SolidMolecular weight:415.88GW768505A free base
CAS:GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2 (pIC50: 7.81 for VEGFR2) with anti-angiogenic activity.Formula:C27H19F4N5O3Color and Shape:SolidMolecular weight:537.47BTK-IN-9
CAS:BTK-IN-9 reversibly inhibits BTK, disrupts mitochondria, boosts ROS, and triggers apoptosis in Z138 cells, impeding condyloma cell growth.Formula:C25H19N7O4Color and Shape:SolidMolecular weight:481.46TYRA-200
CAS:TYRA-200, Oral FGFR1/2/3 inhibitor, induces tumor regression in wild-type/mutant FGFR2 models, for intrahepatic cholangiocarcinoma.Formula:C23H24FN7O2Color and Shape:SolidMolecular weight:449.48YF-452
CAS:YF-452 inhibits tumor growth through antiangiogenesis by suppressing VEGF receptor 2 signaling.Formula:C24H26BrN3OPurity:98%Color and Shape:SolidMolecular weight:452.39Cenisertib benzoate
CAS:Cenisertib benzoate is an orally bioavailable, synthetic, small-molecule multi-Aurora kinase inhibitor with potential antineoplastic activity.Formula:C31H36FN7O3Color and Shape:SolidMolecular weight:573.66Multi-kinase-IN-3
CAS:Multi-kinase-IN-3 (compound 2) is a potent inhibitor of angiokinase and inhibits VEGFR-2 (IC50: 58.3 nM) and PDGFRβ (IC50: 55 nM).Formula:C33H33N5O3Color and Shape:SolidMolecular weight:547.65VEGFR-2-IN-30
VEGFR-2-IN-30: VEGFR-2 inhibitor, IC50 66 nM; blocks PDGFR, EGFR & FGFR1; halts cancer cell cycle, induces apoptosis.Formula:C28H23ClN6O4S2Color and Shape:SolidMolecular weight:607.1DMH4
CAS:DMH4 is a potent and selective inhibitor of VEGFR2 with an IC50 of 0.16 µM.Formula:C24H24N4O2Purity:99.58%Color and Shape:SolidMolecular weight:400.47Peficitinib hydrobromide
CAS:Peficitinib hydrobromide is used in the treatment of Psoriasis and Rheumatoid Arthritis.Formula:C18H23BrN4O2Color and Shape:SolidMolecular weight:407.312
